Kiniksa Pharmaceuticals (NASDAQ:KNSA) Posts Quarterly Earnings Results

Kiniksa Pharmaceuticals (NASDAQ:KNSA) posted its earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17), Briefing.com reports. The firm had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The firm’s revenue for the quarter was up 67.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.20) EPS.

Kiniksa Pharmaceuticals Trading Down 1.2 %

NASDAQ:KNSA opened at $23.00 on Wednesday. Kiniksa Pharmaceuticals has a 12-month low of $14.12 and a 12-month high of $28.15. The stock’s 50 day simple moving average is $25.64 and its 200-day simple moving average is $22.42. The firm has a market cap of $1.64 billion, a P/E ratio of -145.41 and a beta of 0.33.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the transaction, the chief operating officer now directly owns 119,911 shares of the company’s stock, valued at approximately $3,226,805.01. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, COO Eben Tessari sold 17,500 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the sale, the chief operating officer now owns 119,911 shares in the company, valued at $3,226,805.01. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the sale, the insider now directly owns 52,038 shares in the company, valued at $1,359,232.56. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 112,692 shares of company stock valued at $2,950,315 over the last three months. 54.57% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have commented on KNSA shares. Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price target on the stock. Wedbush upped their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, July 23rd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $33.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.